ARTICLE | Clinical News

Pulmozyme DNase data

October 31, 1994 8:00 AM UTC

GNE presented data at the North American Cystic Fibrosis Conference in Orlando showing that Pulmozyme is effective in treating CF patients with severe obstructive lung disease (forced vital capacity < 40 percent). These patients were sicker than the patients tested in GNE's original Phase III study, in which entry was limited to patients whose FVC was > 40 percent of predicted.

A total of 320 patients were recruited in the U.K. and U.S. and treated for three months. Administration of Pulmozyme significantly improved forced expiratory volume in 1 second (FEV1) (7.3 per cent) and FVC (5.1 percent) compared to placebo. ...